SynthesisReviews in medical virology2022
Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis.
Synthesis in Reviews in medical virology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it, 93 citations in OpenAlex.
- Prevalence and classification of anemia among children in Sudan: a systematic review and meta-analysis.Journal of medicine and life · 2024Pooled it
- SARS-CoV-2 infection in Africa: a systematic review and meta-analysis of standardised seroprevalence studies, from January 2020 to December 2021.BMJ global health · 2022Pooled it
- Seroprevalence of anti-SARS-CoV-2 antibodies in Africa: A systematic review and meta-analysis.Reviews in medical virology · 2022Pooled it
- Observational
- Clinical performance of a dual-target SARS CoV-2 antibody assay using sera from Ghana.BMC infectious diseases · 2025Article
- SARS-CoV-2 seroprevalence and COVID-19 vaccination coverage in two states of Nigeria from a population based household survey.Scientific reports · 2025Article
- Safety and immunogenicity of fractional COVID-19 vaccine doses in Nigerian adults: A randomized non-inferiority trial.Scientific reports · 2025Article
- Compartmentalised mucosal and blood immunity to SARS-CoV-2 is associated with high seroprevalence before the Delta wave in Africa.Communications medicine · 2025Article
- Population-based cross-sectional seroprevalence study of SARS-CoV-2 infection in urban residential areas in Ghana.BMJ public health · 2025Article
- Sero-prevalence of SARS-CoV-2 antibodies in Ethiopia: Results of the National Population Based Survey, 2021.PloS one · 2025Article
- Determinants of SARS-CoV-2 infection across three sentinels sites in Benin during 2021: A multicentric surveillance study.PLOS global public health · 2025Article
- Post-Omicron SARS-CoV-2 antibody prevalence in Sierra Leone: A cross-sectional, nationally representative, follow-up serosurvey.PLOS global public health · 2025Article
- SARS-CoV-2 seroprevalence and associated factors among outpatient attendees at health facilities in different provinces in Chad.BMC infectious diseases · 2024Article
- Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: a serial cross-sectional study.medRxiv : the preprint server for health sciences · 2024Article
- IgG and IgM differentiation in a particle-based agglutination assay by control over antigen surface density.APL bioengineering · 2024Article
- High SARS-CoV-2 Exposure in Rural Southern Mozambique After Four Waves of COVID-19: Community-Based Seroepidemiological Surveys.Influenza and other respiratory viruses · 2024Article
- SARS-CoV-2 seroprevalence in vaccine-naïve participants from the Democratic Republic of Congo, Guinea, Liberia, and Mali.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2024Article
- Seroprevalence of SARS-CoV-2 and risk factors for infection among children in Uganda: A serial cross-sectional study.PloS one · 2024Article
- Presence of neutralizing SARS-CoV-2 antibodies in asymptomatic population of N'Djamena, Chad.Immunity, inflammation and disease · 2024Article
- COVID-19 vaccination implementation in 52 African countries: trajectory and implications for future pandemic preparedness.BMJ global health · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We estimated the seroprevalence of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in residents of African countries and explored its associated factors. We searched PubMed, EMBASE, PsycINFO, AMED, CINAHL, DOAJ and Google Scholar databases for peer reviewed articles and pre-prints that reported anti-SARS-CoV-2 antibody seroprevalence of general or specific human populations resident in Africa. The eligible studies were evaluated using Joana Briggs Institute prevalence critical appraisal tool. Twenty-three studies involving 27,735 individuals were included in our paper. The pooled seroprevalence of anti-SARS-CoV-2 antibodies in Africa was 22% (95%CI: 14-31) with very high heterogeneity (I
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.